A 34 year old female has axSpA. Her CRP is 3, her MRI is quiet, and her BASDAI is 7. She has tried two biologics and is asking about a third. Before we write that prescription, #ACR26 challenges us to ask a different question: is it still inflammation?
All News
Article
New FDA Approved for Polymyalgia Rheumatica - Secukinumab
The US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate a https://t.co/kmgEiZIiFS
Biologics vs JAKi: MACE and VTE Risk in PsA
Dr. Sheila Reyes & Dr. Marina Magrey | Abstract 2304 | ACR 2026
https://t.co/IzafHHg9Me https://t.co/PGfQOk882R
JAKi CV Safety in Younger Adults
https://t.co/Cp7YEz0277 https://t.co/oBGRQjBuoH
UPSTAND study: widespread pain responding to JAK inhibition
https://t.co/ZGouZSXaXU https://t.co/He2nXncsFF
David Liew
Tweet
Is 60-40-20 broken?
RA trial rule of thumb:
roughly 60%-40%-20% for ACR20-50-70
girocitinib (JAK1/Tyk2) vs tofacitinib
ACR20: 91% vs 75%
ACR50: 73% vs 49%
ACR70: 44% vs 25%
there will be debate (all in China, tofa exposure)
but what a meeting for H2H
ABSTLB21 #ACR26 @RheumNow https://t.co/SmOCzqqxFg
David Liew
Tweet
Great @RheumNow Day 2 Daily Recap today talking about trends in SpA therapy, PsA and obesity, gout flares and CV risk, IL-17/23 in PMR/GCA, and as always a healthy dose of 'AI is coming/here'. All the good stuff from #ACR26 with @synovialjoints @AdelaCastro222 @ericdeinmd https://t.co/FSjr2Qn3JC
Brian Jaros, MD
Tweet
Just as tofacitinib goes generic, have we found a better option?
TARA = giroctinib (JAK1/TYK2) vs. tofa in severe/refractory RA
39% with prior JAK exposure
Week 4: ACR50 ~15% vs. 6%
Week 24: ACR50 73% vs. ~50%
Similar infx risk esp zoster, no MACE
@RheumNow #ACR26 LB21 https://t.co/ZthsWSoedR
Akhil Sood MD, MS
Tweet
Another potential treatment for treating Sjogren's:
LB22: Ph3b efficacy & safety of Dazodalibep (DZP), CD40/CD40L inhbition
VS PBO:
- Wk 48; both DZP regimens improved ESDAI (diff v PBO -1.8 & -1.4)
- tx effect early as wk 4
- Pt reported dryness also improved
@RheumNow #ACR26 https://t.co/qa4dyr3e40
LB21: TARA - Phase 3, DB, active-controlled RCT
Girocitinib (TLL-018) - highly selective JAK1/TYK2 dual inhibitor - vs JAKi in active RA refractory to bDMARDs
ACR50 at 24wks: 73.0% versus 49.5%
Potential option for D2T RA?!
#ACR26 @RheumNow https://t.co/SGkZjP994P
TARA phase 3 (n=459): after bDMARD failure, week-24 ACR50 was 73.0% with girocitinib vs 49.5% with tofacitinib (p<0.0001). Serious infections: 3 vs 4. Findings support girocitinib as a promising treatment option for refractory RA. #LB21 #ACR26 @Rheumnow https://t.co/mjWW8GgRkm
Janet Pope
Tweet
#girocitinib #JAK1/TYK2 v JAK1 #tofacitinib
Good safety profile
1 thrombosis in #tofa
Better outcomes
🛑 Tofa-IR allowed
#ACR26 @RheumNow @ACRheum #LB21 https://t.co/6WJko54SRm
Audrey Gibson
Tweet
Zeng et al: TARA phase 3 in bDMARD-refractory RA: Week 24 ACR50 was 73.0% with girocitinib vs 49.5% with tofacitinib (p<0.0001). Impressive efficacy; longer-term safety remains critical. @rheumnow #ACR2026 Abstract#LB21
Janet Pope
Tweet
#JAK1/#TYK2i #girocitinib #H2H v #tofacitinib
TARA RCT in #RA in #China post #bDMARD(s) #IR or #intolerance
🏆 Girocitinib 20mg bid n=450, low drop out
#ACR50 wk24 and crossover of Tofa to Giro if not met
Could be #JAKi exposed
?when to use
?other pop
#LB21 #ACR26 @RheumNow https://t.co/dR2lsB6CGJ
David Liew
Tweet
The late breaking abstracts are nearly here! And my most anticipated one: TARA Remember TLL-018, the Chinese JAK1/Tyk2 at #EULAR2023, smashing tofa in RA? https://t.co/bu5syrTaWQ We said: come back with your ph3 data They did. Same results ABSTLB21 #ACR26 #ACRBest @RheumNow https://t.co/9SmW54dPia
sheila
Tweet
TARA trial: Ph3 H2H trial of Girocitinib (JAK1/TYK2i) vs Tofa in RA refractory to bDMARDs
Giro achieved higher ACR50 response vs Tofa at wk24 (73 vs 49.5%)
Also met secondary endpts
Safety data: Infections more common. No VT/malignancy/MACE in Giro arm.
@RheumNow #ACR26 LB21 https://t.co/HNVt7WdLc6
Richard Conway
Tweet
Zeng et al. TARA phase 3 RCT from China. 459 bDMARD-IR patients. Girocitinib (JAK1/TYK2i) superior to tofacitinib in RA. Better by week 4 and increasingly so over time. Numerically less serious adverse events 3.9% vs 6.6% also. @RheumNow #ACR26 Abstr#LB21 #ACRbest https://t.co/Yt406T3eyi
Janet Pope
Tweet
NO small feat!
A nanoparticle target of
Myeloid inhibiting #JAK in #RA
Some JAK #dendranib candidates have been found and are being studied
Cool technology- need to follow this space
#2028 #ACR26 @ACRheum @RheumNow https://t.co/X9E5LzyY0h
Janet Pope
Tweet
Knowledge doesn’t ‘LAG’ in #RA T cell inhibition
#LAG-3 is inhibited by #IMP761
⬇️T cell activation &proliferation in RA
Strong rationale to consider new #MOA at higher doses
Too early to know for sure re future efficacy but sound rational
#LB09 #ACR26 @ACRheum @RheumNow https://t.co/AUjeWEIbaB
